Key result
LDE-MTX fails to improve LVEDV at 90 days vs placebo, despite reducing infarct size.
Why the study?
Does intravenous methotrexate carried by lipid nanoemulsion (LDE-MTX) improve left ventricle end-diastolic volume in patients with anterior ST-elevation myocardial infarction?
RCT (n=32)
Randomized
Does intravenous methotrexate carried by lipid nanoemulsion (LDE-MTX) improve left ventricle end-diastolic volume in patients with anterior ST-elevation myocardial infarction?
Answers are grounded in this paper and cite their sources.
In patients with anterior STEMI, intravenous LDE-MTX did not improve left ventricular end-diastolic volume at 90 days but was safe and may reduce infarct size, warranting further investigation.
Background: Inflammation plays a central role in the pathophysiology of ST-elevation myocardial infarction (STEMI), being associated with larger infarct size (IS) and worse left ventricular remodeling (LVR). Methotrexate (MTX) is a potent anti-inflammatory drug with potential benefits in the treatment of STEMI. Experimental studies have suggested that a formulation of MTX incorporated into lipid nanoemulsion (LDE-MTX) could be beneficial and safe. Objectives: To evaluate the efficacy and safety of LDE-MTX in patients with STEMI. Methods: intravenous infusion) or LDE-placebo weekly for 6 weeks. The primary efficacy endpoint was left ventricle end-diastolic volume (LVEDV) assessed by cardiac magnetic resonance at 90 ± 7 days post-randomization; the main secondary endpoints were changes in LVEDV, other LVR parameters and IS. Results: Due to the COVID-19 pandemic the study was stopped prematurely, with 32 randomized patients (15 LDE-placebo, 17 LDE-MTX) completing the protocol. At 90 days, there was no difference in LVEDV between groups. Among other secondary endpoints, there appeared to be a greater reduction of IS (%LV) in favor of the LDE-MTX group (-3.9 ± 6.9 vs -9.4 ± 8.4, p = 0.030). LDE-MTX was well tolerated. Conclusions: In patients with STEMI, LDE-MTX appears to be safe but did not influence LVEDV and other LVR parameters, although it possibly reduced infarct size at 90 days. These hypothesis-generating results support further investigation of a novel nanomedicine approach to STEMI in larger trials.
No takes yet. Share an insight, caveat, or question.
Ferrari et al. (2025) conducted an RCT in Anterior ST-elevation myocardial infarction (n=32). Intravenous methotrexate carried by lipid nanoemulsion (LDE-MTX) vs. LDE-placebo was evaluated on Left ventricle end-diastolic volume (LVEDV) assessed by cardiac magnetic resonance at 90 ± 7 days post-randomization. Intravenous LDE-MTX did not change left ventricle end-diastolic volume at 90 days compared to placebo, but reduced infarct size.
Synapse has enriched 10 related papers. Consider them for comparative context: